| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679086 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
May, 2037
(13 years from now) | |
| US10300025 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(13 years from now) | |
| US10016372 | CORIUM | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(13 years from now) | |
| US10307379 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(13 years from now) | |
| US9993466 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(13 years from now) | |
| US11103463 | CORIUM | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(13 years from now) | |
| US11648214 | CORIUM | Systems and methods for long term transdermal administration |
Sep, 2037
(13 years from now) | |
| US10835499 | CORIUM | Systems and methods for long term transdermal administration |
May, 2038
(14 years from now) | |
| US10966936 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
Aug, 2038
(14 years from now) | |
Adlarity is owned by Corium.
Adlarity contains Donepezil Hydrochloride.
Adlarity has a total of 9 drug patents out of which 0 drug patents have expired.
Adlarity was authorised for market use on 11 March, 2022.
Adlarity is available in system;transdermal dosage forms.
Adlarity can be used as a method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type.
The generics of Adlarity are possible to be released after 11 August, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM;TRANSDERMAL
ADLARITY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic